Skip to main content
. 2020 May 20;15:1135–1142. doi: 10.2147/COPD.S242809

Table 1.

Association Between Lung Function Indices and Time to Mortality, Cardiovascular Events, Moderate and Severe Exacerbations, and Severe Exacerbations

Time to Death Risk Reduction vs. Q1 Time to First Major Cardiovascular Event 
Risk Reduction vs. Q1
Time to First Moderate/Severe Exacerbation Risk Reduction vs. Q1 Time to First Severe Exacerbation Risk Reduction vs. Q1
FEV1% Predicted Q1 <53.5%
Q2 53.5 to 57.5% 20% (4 to 34%) 5% (−20 to 25%) 11% (3 to 19%) 10% (−5 to 23%)
Q3 57.5 to 61.6% 28% (13 to 40%) 15% (−8 to 33%) 15% (7 to 22%) 25% (12 to 37%)
Q4 61.6 to 65.8 23% (7 to 36%) 9% (−15 to 28%) 23% (16 to 30%) 37% (25 to 47%)
Q5 ≥65.8% 30% (15 to 42%) 7% (−18 to 26%) 27% (20 to 33%) 40% (28 to 49%)
FVC % Predicted Q1 <67.4%
Q2 67.4 to 73.6% 14% (−4 to 29%) 16% (−7 to 34%) 2% (−8 to 10%) 4% (−15 to 20%)
Q3 73.6 to 79.5% 11% (−8 to 27%) −4% (−30 to 17%) −4% (−14 to 5%) 0% (−20 to 17%)
Q4 79.5 to 87.6% 14% (−4 to 29%) 11% (−13 to 29%) −6% (−17 to 3%) −13% (−34 to 6%)
Q5 ≥87.6% 21% (4 to 35%) 21% (−1 to 38%) −22% (−34 to −11%) −28% (−52 to −8%)
FEV1/FVC Q1 <0.51
Q2 0.51 to 0.57 0% (−21 to 16%) −7% (−36 to 16%) 18% (11 to 25%) 22% (9 to 33%)
Q3 0.57 to 0.62 7% (−12 to 24%) −8% (−38 to 15%) 28% (22 to 35%) 39% (28 to 49%)
Q4 0.62 to 0.66 10% (−10 to 26%) −12% (−43 to 12%) 29% (22 to 35%) 41% (29 to 50%)
Q5 ≥0.66 −5% (−28 to 14%) −18% (−50 to 8%) 36% (30 to 42%) 48% (37 to 57%)

Notes: Results are from Cox Proportional Hazard models and are presented as risk reduction compared with Q1 quintile groups (with 95% confidence intervals). These are calculated as (1–hazard ratio) × 100. Negative % reductions indicate increase in risk, i.e., hazard ratio >1. Nominally significant differences are presented in bold (p<0.05, no adjustment for multiplicity).

Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity.